Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Leukemia

• Publication date

  2010-04-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2010.52PMID 20376084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

  2010cited by this paper
• Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.

  2010cited by this paper
• Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

  2010cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity*

  2004cited by this paper

• Reversible arginine methylation regulates mitochondrial IDH2 activity: coordinated control by CARM1 and KDM3A/4A

  2026cites this paper
• Therapeutic targeting of chromatin alterations in leukemia and solid tumors

  2025cites this paper
• Advances and challenges in the treatment of myelodysplastic syndromes

  2025cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025.

  2025cites this paper
• Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.

  2025cites this paper
• A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia

  2025cites this paper
• Gaining Insight into the Catalytic Mechanism of the R132H IDH1 Mutant: A Synergistic DFT Cluster and Experimental Investigation.

  2024cites this paper
• AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular

  2024cites this paper
• DNA methylation in human diseases

  2024cites this paper
• Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials

  2024cites this paper
• A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms

  2024cites this paper
• How we diagnose Myelodysplastic syndromes

  2024cites this paper
• [Treating high-risk myelodysplastic syndromes].

  2023cites this paper
• Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

  2023influential citation
• Research progress on the pathogenesis of the SDHB mutation and related diseases.

  2023cites this paper
• The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches

  2023cites this paper
• IDH2 mutations in acute myeloid leukemia

  2023cites this paper
• Molecular alterations in IDH 1/2 genes among Iraqi adult acute myeloid leukemia patients: Their response to treatment

  2023cites this paper
• IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders

  2022cites this paper
• In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia—A Narrative Review of Current Knowledge

  2022cites this paper
• Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

  2022cites this paper
• A phase 1 study of IDH305 in patients with IDH1^R132-mutant acute myeloid leukemia or myelodysplastic syndrome

  2022cites this paper
• Co‐mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome

  2022cites this paper
• The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions

  2022cites this paper
• Therapeutic approaches for the management of higher risk myelodysplastic syndromes

  2022cites this paper
• Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

  2022cites this paper
• NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

  2022cites this paper
• New Approaches with Precision Medicine in Adult Brain Tumors

  2022cites this paper
• Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective

  2021cites this paper
• Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer

  2021cites this paper
• Discovery and Development of Ivosidenib (AG‐120: TIBSOVO ®  )

  2021cites this paper
• Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity

  2021cites this paper
• G-protein-coupled receptors as therapeutic targets for glioblastoma.

  2021cites this paper
• A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.

  2021cites this paper
• Pediatric Acute Lymphoblastic Leukemia With Hypereosinophilia and IDH2 Gene Mutation: A Case Report and Literature Review.

  2021cites this paper
• BLCTT_A_236446 41..54

  2021cites this paper
• Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/β-catenin signalling

  2021cites this paper
• Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence

  2021cites this paper
• An IDH1-vitamin C crosstalk drives human erythroid development by inhibiting pro-oxidant mitochondrial metabolism.

  2020cites this paper
• Myelodysplastic Syndromes

  2020cites this paper
• IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.

  2020cites this paper
• Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation

  2020cites this paper
• Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.

  2020cites this paper
• Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges

  2020cites this paper
• Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.

  2020cites this paper
• Isocitrate Dehydrogenase 2 Inhibitors for the treatment of Hematologic Malignancies: Advances and Future Opportunities.

  2020cites this paper
• MicroRNA-145 promotes the apoptosis of leukemic stem cells and enhances drug-resistant K562/ADM cell sensitivity to adriamycin via the regulation of ABCE1

  2020cites this paper
• Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

  2020cites this paper
• Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients

  2020cites this paper
• Metabolic Changes and Their Characterization

  2020cites this paper
• The chromatin remodeler LSH controls genome-wide cytosine hydroxymethylation

  2020cites this paper
• Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells

  2020cites this paper
• New Agents in the Treatment of Acute Myeloid Leukemia

  2020cites this paper
• Targeting isocitrate dehydrogenase mutations (IDH) in AML: wielding the double-edged sword of differentiation.

  2020cites this paper
• Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes

  2020cites this paper
• An acidic residue buried in the dimer interface of isocitrate dehydrogenase 1 (IDH1) helps regulate catalysis and pH sensitivity

  2020cites this paper
• Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma.

  2020cites this paper
• Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation

  2020cites this paper
• Altered cancer metabolism in mechanisms of immunotherapy resistance

  2019cites this paper
• Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.

  2019cites this paper
• Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

  2019cites this paper
• An evaluation of enasidenib for the treatment of acute myeloid leukemia

  2019cites this paper
• Warburg and Krebs and related effects in cancer

  2019cites this paper
• Water networks and correlated motions in mutant IDH1 are critical for allosteric inhibitor binding and activity.

  2019cites this paper
• Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications

  2019cites this paper
• Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans

  2019cites this paper
• Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors.

  2019cites this paper
• What are the most promising new agents in myelodysplastic syndromes?

  2019cites this paper
• Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy.

  2019cites this paper
• An update on treatment of higher risk myelodysplastic syndromes

  2018cites this paper
• Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas

  2018cites this paper
• Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy

  2018cites this paper
• Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes

  2018cites this paper
• Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.

  2018cites this paper
• IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?

  2018cites this paper
• From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes

  2018cites this paper
• Isocitrate dehydrogenase 1 mutations in melanoma frequently co‐occur with NRAS mutations

  2018cites this paper
• Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.

  2018cites this paper
• Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

  2018cites this paper
• The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia

  2018cites this paper
• Neoplastische Bildungsstörungen der Hämatopoiese mit erhaltener Ausreifung

  2018cites this paper
• Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

  2017cites this paper
• The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia

  2017cites this paper
• Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup

  2017cites this paper
• Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight

  2017cites this paper
• Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms

  2017cites this paper
• Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia

  2017cites this paper
• Novel epigenetic therapies in hematological malignancies: Current status and beyond.

  2017cites this paper
• Marked for death: targeting epigenetic changes in cancer

  2017cites this paper
• Targeted Differentiation Therapy with Mutant IDH Inhibitors: Early Experiences and Parallels with Other Differentiation Agents

  2017cites this paper
• IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes

  2017cites this paper
• IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage

  2017cites this paper
• Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone

  2017cites this paper
• Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.

  2017cites this paper
• TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes

  2017cites this paper
• IDH mutations associated impact on related cancer epidemiology and subsequent effect toward HIF-1α.

  2017cites this paper
• The emerging role and targetability of the TCA cycle in cancer metabolism

  2017cites this paper
• Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing

  2017cites this paper
• AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

  2017cites this paper
• Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling

  2017cites this paper